SciVision Biotech Inc Total Liabilities
SciVision Biotech Inc total liabilities. Based on the latest financial reports, SciVision Biotech Inc (1786) has total liabilities worth NT$892.04 Million TWD (≈ $28.10 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 1786 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SciVision Biotech Inc (2009–2025)
Total liabilities of SciVision Biotech Inc from 2009 to 2025. This chart illustrates how SciVision Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore SciVision Biotech Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
SciVision Biotech Inc Competitors by Total Liabilities
The table below lists competitors of SciVision Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Borosil Scientific
NSE:BOROSCI
|
India | Rs1.08 Billion |
|
Super Energy Corporation Public Company Limited
BK:SUPER
|
Thailand | ฿50.73 Billion |
|
Hennessy Capital Investment Corp VI
NASDAQ:HCVI
|
USA | $27.66 Million |
|
Western Carriers India Ltd
NSE:WCIL
|
India | Rs3.38 Billion |
|
ReaLy Development & Construction
TWO:2596
|
Taiwan | NT$3.78 Billion |
|
NIBEC Co. Ltd
KQ:138610
|
Korea | ₩16.60 Billion |
|
Supercomnet Technologies Bhd
KLSE:0001
|
Malaysia | RM21.42 Million |
|
The Hi-Tech Gears Limited
NSE:HITECHGEAR
|
India | Rs3.17 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down SciVision Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 1786 total assets.
Liquidity & Leverage Metrics
SciVision Biotech Inc Total Liabilities Ratios Explained
SciVision Biotech Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SciVision Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SciVision Biotech Inc (2009–2025)
The table below shows the annual total liabilities of SciVision Biotech Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$689.35 Million ≈ $21.72 Million |
+50.70% |
| 2024-12-31 | NT$457.43 Million ≈ $14.41 Million |
-14.29% |
| 2023-12-31 | NT$533.66 Million ≈ $16.81 Million |
-9.13% |
| 2022-12-31 | NT$587.30 Million ≈ $18.50 Million |
-27.68% |
| 2021-12-31 | NT$812.06 Million ≈ $25.58 Million |
+66.90% |
| 2020-12-31 | NT$486.55 Million ≈ $15.33 Million |
-2.90% |
| 2019-12-31 | NT$501.08 Million ≈ $15.79 Million |
-18.88% |
| 2018-12-31 | NT$617.70 Million ≈ $19.46 Million |
-4.78% |
| 2017-12-31 | NT$648.72 Million ≈ $20.44 Million |
+40.13% |
| 2016-12-31 | NT$462.93 Million ≈ $14.58 Million |
+272.86% |
| 2015-12-31 | NT$124.16 Million ≈ $3.91 Million |
+80.43% |
| 2014-12-31 | NT$68.81 Million ≈ $2.17 Million |
+52.13% |
| 2013-12-31 | NT$45.23 Million ≈ $1.43 Million |
-21.07% |
| 2012-12-31 | NT$57.31 Million ≈ $1.81 Million |
+42.67% |
| 2011-12-31 | NT$40.17 Million ≈ $1.27 Million |
-63.89% |
| 2010-12-31 | NT$111.24 Million ≈ $3.50 Million |
+6.64% |
| 2009-12-31 | NT$104.31 Million ≈ $3.29 Million |
-- |
About SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more